TP53 alterations independently predicted inferior remission, EFS, and OS after CAR T-cell therapy in relapsed/refractory B-ALL.
(TP53), widely known as the “guardian of the genome,” is one of the most frequently altered genes in human cancer. While its canonical tumor-suppressive ...
Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...
Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with ...
Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53. People with myelofibrosis (MF) who undergo hematopoietic stem cell transplantation ...
Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free ...
The TP53 gene provides instructions for making a protein called tumor protein p53 (or p53). This protein regulates cell division by keeping cells from growing and dividing too fast or in an ...
Men who have mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found. The findings were reported in the ...
Cate Hargett from Greenwood, MS urgently needs a bone marrow transplant due to a TP53 mutation, and donor drives are being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results